Ibogaine's cardiac safety profile causes at least one major clinical trial sponsor to publicly pause or redesign an ibogaine IND before December 31, 2027

The original prediction conflated two separate claims (2+ year delay AND oxa-noribogaine preferred candidate) into one unfalsifiable compound statement. Separated here into a falsifiable regulatory-behavior claim. QT prolongation data from scoping reviews is now sufficient to trigger FDA clinical holds or sponsor-initiated protocol amendments. At least one active IND (ATAI, DemeRx, or VA-affiliated) is likely to require cardiac monitoring redesign or suspension. Resolve criteria: public SEC filing, press release, or FDA correspondence confirming pause or redesign of an ibogaine IND citing cardiac safety. Confidence 0.70 reflects strong mechanistic basis but uncertainty about which sponsor acts first and timing.